Tesetaxel

Drug Profile

Tesetaxel

Alternative Names: DJ-927

Latest Information Update: 04 Mar 2015

Price : $50

At a glance

  • Originator Daiichi Pharmaceutical
  • Developer Genta (CEASED)
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Malignant melanoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bladder cancer; Breast cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Prostate cancer; Solid tumours

Most Recent Events

  • 01 Oct 2014 M.D Anderson Cancer Center in collaboration with Genta Incorporated terminates a phase II trial in Malignant melanoma (Second-line therapy or greater) in USA (NCT01064713)
  • 15 Jul 2012 Genta completes enrolment in its phase II trial for Malignant melanoma (second-line therapy) in US (NCT01064713)
  • 31 May 2012 Genta initiates enrolment in a phase IIb trial for Breast cancer (first-line therapy, advanced or recurrent disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top